PCSK9 and atherosclerosis: Evolocumab, a new lipid-lowering drug, is a fully human monoclonal antibody against PCSK9, which is able to prevent the hepatic LDL-R degradation induced by PCSK9, finally reducing the risk of ASCVD and limb events [9].